Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299,105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NOTCH1 drives sexually dimorphic immune responses in hepatocellular carcinoma.
Lindblad KE, Donne R, Liebling I, Barcena-Varela M, Lozano A, Ruiz de Galarreta M, Dhainaut M, Param NJ, Giotti B, Cappuyns S, Kodama T, Wang Y, Kamphorst AO, Tsankov AM, Lujambio A. Lindblad KE, et al. Among authors: wang y. Cancer Discov. 2024 Nov 19. doi: 10.1158/2159-8290.CD-24-1215. Online ahead of print. Cancer Discov. 2024. PMID: 39560425
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Zhu AX, et al. Among authors: wang y. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. Nat Med. 2022. PMID: 35739268
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).
Makker V, Recio FO, Ma L, Matulonis UA, Lauchle JO, Parmar H, Gilbert HN, Ware JA, Zhu R, Lu S, Huw LY, Wang Y, Koeppen H, Spoerke JM, Lackner MR, Aghajanian CA. Makker V, et al. Among authors: wang y. Cancer. 2016 Nov 15;122(22):3519-3528. doi: 10.1002/cncr.30286. Epub 2016 Sep 7. Cancer. 2016. PMID: 27603005 Free PMC article.
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers.
Lehrich BM, Delgado ER, Yasaka TM, Liu S, Cao C, Liu Y, Taheri M, Guan X, Koeppen H, Singh S, Liu JJ, Singh-Varma A, Krutsenko Y, Poddar M, Hitchens TK, Foley LM, Liang B, Rialdi A, Rai RP, Patel P, Riley M, Bell A, Raeman R, Dadali T, Luke JJ, Guccione E, Ebrahimkhani MR, Lujambio A, Chen X, Maier M, Wang Y, Broom W, Tao J, Monga SP. Lehrich BM, et al. Among authors: wang y. Res Sq [Preprint]. 2024 Dec 12:rs.3.rs-5494074. doi: 10.21203/rs.3.rs-5494074/v1. Res Sq. 2024. PMID: 39711542 Free PMC article. Preprint.
Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer.
Hornburg M, Desbois M, Lu S, Guan Y, Lo AA, Kaufman S, Elrod A, Lotstein A, DesRochers TM, Munoz-Rodriguez JL, Wang X, Giltnane J, Mayba O, Turley SJ, Bourgon R, Daemen A, Wang Y. Hornburg M, et al. Among authors: wang x, wang y. Cancer Cell. 2021 Jul 12;39(7):928-944.e6. doi: 10.1016/j.ccell.2021.04.004. Epub 2021 May 6. Cancer Cell. 2021. PMID: 33961783 Free article.
Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors.
Castiglioni A, Yang Y, Williams K, Gogineni A, Lane RS, Wang AW, Shyer JA, Zhang Z, Mittman S, Gutierrez A, Astarita JL, Thai M, Hung J, Yang YA, Pourmohamad T, Himmels P, De Simone M, Elstrott J, Capietto AH, Cubas R, Modrusan Z, Sandoval W, Ziai J, Gould SE, Fu W, Wang Y, Koerber JT, Sanjabi S, Mellman I, Turley SJ, Müller S. Castiglioni A, et al. Among authors: wang y, wang aw. Nat Commun. 2023 Aug 5;14(1):4703. doi: 10.1038/s41467-023-40398-4. Nat Commun. 2023. PMID: 37543621 Free PMC article.
Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma.
Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y. Kaseb AO, et al. Among authors: wang y. J Hepatocell Carcinoma. 2022 Oct 11;9:1065-1079. doi: 10.2147/JHC.S369951. eCollection 2022. J Hepatocell Carcinoma. 2022. PMID: 36254201 Free PMC article.
299,105 results
You have reached the last available page of results. Please see the User Guide for more information.